| Name | Title | Contact Details |
|---|
Stellar Biotechnologies is a world leader in the development and manufacture of keyhole limpet hemocyanin (KLH).
Founded by industry pioneers who championed the world`s leading hemp CBD genetics, formulations and spearheaded groundbreaking US hemp legislation, GenCanna ™ is focused on scaling our premium hemp genetics production for food products with easy availability locally, nationally and globally.
BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.